Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.48 |
| ▸ | SGK1 | O00141 | 4/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.40 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20486322 | 0.87 | SLC22A12 (0.48) | SLC22A12SCN9ASGK1SCN3A | |
| SCHEMBL20182483 | 0.72 | SCN5A (0.62) | SCN9ASCN1ASCN5ASCN8ASCN1B | |
| SCHEMBL20238048 | 0.72 | SCN8A (0.56) | SCN9ASGK1SCN1ASCN5ASCN8A | |
| SCHEMBL20238558 | 0.72 | SCN5A (0.59) | SLC22A12SCN9ASGK1SCN1ASCN5A | |
| SCHEMBL19614071 | 0.72 | SCN1A (0.65) | SCN9ASCN1ASCN5ASCN8ASCN1B | |
| SCHEMBL1095172 | 0.71 | SCN5A (0.61) | SCN9ASCN1ASCN5ASCN8ASCN1B | |
| SCHEMBL30646286 | 0.71 | ALPL (0.54) | SCN9ASGK1 | |
| Hydrochloric Acid SCHEMBL20486310 | 0.71 | SCN5A (0.60) | SCN9ASCN1ASCN5ASCN8ASCN1B | |
| SCHEMBL16757015 | 0.70 | SCN1A (0.62) | SCN9ASCN1ASCN5ASCN8A | |
| SCHEMBL29668849 | 0.69 | SCN9A (0.55) | SLC22A12SCN9ASCN3ASCN1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-06-11 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2590972-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DDT, ALKBH5, DDO | SLC22A12 4678/4885SCN9A 3799/4885SGK1 2705/4885 |
| US-20130109667-A1 | Chemical Compounds | SCN1A, SCN7A, SCN1B | SLC22A12 1897/4885SCN9A 11/4885SGK1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.